Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
refametinib + gemcitabine
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Refametinib (BAY86-9766) is a potent and highly selective allosteric inhibitor of MEK1 and MEK2 kinases. It acts by inhibiting the phosphorylation of ERK, thereby blocking the MAPK/ERK signaling pathway involved in cell proliferation and survival. Refametinib has demonstrated antitumor activity in preclinical models of various cancers including melanoma, colorectal cancer, non-small cell lung cancer, epidermal carcinoma, and hepatocellular carcinoma. Gemcitabine is a nucleoside analog used as chemotherapy that inhibits DNA synthesis. The combination of refametinib with gemcitabine has been investigated in early-phase clinical trials for advanced or refractory solid tumors to evaluate safety and pharmacokinetics[1][3][4].
- Other names
- refametinib + gemcitabineBAY 86-9766 + gemcitabine
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)DNA polymerase family
Beyond the preview
Go deeper on refametinib + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on refametinib + gemcitabine.